Cervical Cancer
Conditions
Interventions
Morning-irradiated group:Irradiated at 9:00-11:00. External radiation: 6-MV X ray, whole pelvic DT30-40GY/15-20F, four-field DT10-20GY/5-10F, 2GY/F. After-loading therapy: DT42GY/7-8F, 5-6 GY/F.
Evening-irradiated group:Irradiated at 21:00-23:00. External radiation: 6-MV X ray, whole pelvic DT30-40GY/15-20F, four-field DT10-20GY/5-10F, 2GY/F. After-loading therapy: DT42GY/7-8F, 5-6 GY/F.
Sponsors
Tumor Hospital of Yunnan Province (The Third Affliated Hospital of Kunming Medical College)
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Female aged 18 to 65 years old; 2. Able and willing to provide signed informed consent; 3. Patients with clinical stage IIb-IVa cervical carcinoma; 4. Patients had an ECOG performance status 0 to 2; 5. Cervical carcinoma without distant metastasis; 6. Patients have never received pelvic cavity radiotherapy and haven't receive systemic chemotherapy in 4 weeks before; 7. Pregnancy test results are negative; 8. Normal bone marrow hemopoiesis; 9. Normal hepatic and renal function; 10. Patients without important systems dysfunction and serious malnutrition.
Exclusion criteria
Exclusion criteria: 1. Patients have other carcinoma in situ; 2. Contraindication to radiotherapy on other organs; 3. Patients who is participating or planning to participate in other clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cell cycle;Circadian gene expression;DNA damages;Cell apotosis;Short-term effect;Acute radiation damage; | — |
Secondary
| Measure | Time frame |
|---|---|
| Survival rate;Tumor markers;Micronucleated cell;Biochemistry exmamination;Late complication;GSH concentration;Median survival time (MST);Blood routine test;HPV DNA; | — |
Countries
China
Contacts
Public ContactWenhui Li
Outcome results
None listed